BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 64.68 P/S
- 17.05 P/B
- -0.72 EPS
- -229.93% Cash ROIC
- 1.26 Cash Ratio
- 0 / N/A % Dividend
- 893,690.00 Avg. Vol.
- 72.35M Shares
- 1.12B Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
Insider Trading Report - Jul 6, 2015
Triangle Business Journal - Jun 17, 2015
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza ... - GlobeNewswire (press release)
Street Report - Jul 1, 2015
BioCryst Pharmaceuticals Stock Rating Upgraded by Bank of America (BCRX) - The Legacy
Benzinga - Jun 30, 2015
BioCryst Pharmaceuticals Upgraded to "Buy" by Bank of America (BCRX) - sleekmoney
OTC Outlook - Jul 6, 2015
Insider Trading Report - Jun 25, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Stock Insider Sale - Jon ... - OctaFinance.com
Motley Fool - Apr 1, 2015
BioCryst Awarded BCX4430 Advanced Development Contract - MarketWatch
OctaFinance.com - Jun 2, 2015
Company Insider Thomas R Ii Staab Sells 3000 Shares of Biocryst ... - The Daily Rover
Street Report - Jun 17, 2015
Closing Bell Reports: BioCryst Pharmaceuticals, Inc. (BCRX), Archer-Daniels ... - WallStreet Scope
Insider Trading Report - Jun 12, 2015